tiprankstipranks
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market
2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:2315 full AI Analyst Report?

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Revenue

1 Followers
StatisticsMarket CapRevenue

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Revenue

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had a revenue of 757.85M in the quarter ending Dec 31, 2025, with 22.04%. This bring the company's revenue in the last twelve months to 1.38B, Decreased 15.78%. In the fiscal year ending Dec 31, 2025, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had annual revenue of 1.38B with 40.63% growth.
Revenue (ttm)
1.38B
Revenue Growth
48.38%
P/S Ratio
14.99
Revenue/Employee
HK$1,234,385
Employees
1,117
Market Cap
HK$20.67B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2025
1.38B398.35M+40.63%
Dec 31, 2024
980.45M263.54M+36.76%
Dec 31, 2023
716.91M183.03M+34.28%
Dec 31, 2022
533.88M179.33M+50.58%
Dec 31, 2021
354.56M101.01M+39.84%
Dec 31, 2020
253.54M――